Skip to the page

Data / Drug companies / Oceanside Pharmaceuticals

Oceanside Pharmaceuticals: 78 products in the FDA NDC directory, labeler code 68682

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Oceanside Pharmaceuticals (labeler code 68682) lists 78 products in the FDA National Drug Code Directory, covering 36 finished drugs by generic name. By type: 78 prescription drugs. Its main marketing category is authorized generics (NDA). The newest product started marketing on June 29, 2026.

The request: Watch Oceanside Pharmaceuticals (FDA labeler code 68682): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
68682
Products in commercial distribution
78
Packages
104
Finished drugs by generic name
36
Prescription products
78
Over the counter products
0
Controlled substance products
Schedule III 1, Schedule IV 3
Flagged as original packager
78 of 78 products that carry the flag
Started marketing in the last 12 months
3
Products with a marketing end date set
6
Earliest marketing start
January 10, 1967
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Authorized generics (NDA)5064.1%
Generic drugs (ANDA)1823.1%
New drug applications (NDA)1012.8%

Products by type

TypeProductsShare
Prescription drugs78100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1721.8%
Tablet, extended release1316.7%
Gel1114.1%
Capsule, extended release1012.8%
Cream67.7%
Tablet, film coated, extended release56.4%
Kit33.8%
Solution22.6%
Spray, metered22.6%
Solution/ drops11.3%
Aerosol, foam11.3%
Lotion11.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Bupropion Hydrobromide68682-582Tablet, extended releaseAuthorized generics (NDA)June 29, 2026
Bupropion Hydrobromide68682-581Tablet, extended releaseAuthorized generics (NDA)June 29, 2026
Bupropion Hydrobromide68682-580Tablet, extended releaseAuthorized generics (NDA)June 29, 2026
Ipratropium Bromide68682-399Spray, meteredGeneric drugs (ANDA)June 1, 2025
Ipratroprium Bromide68682-398Spray, meteredGeneric drugs (ANDA)June 1, 2025
Flunisolide68682-344SolutionGeneric drugs (ANDA)June 1, 2025
Desmopressin Acetate68682-342SolutionGeneric drugs (ANDA)June 1, 2025
Tretinoin68682-515GelAuthorized generics (NDA)December 1, 2023
Clindamycin Phosphate and Benzoyl Peroxide68682-133GelAuthorized generics (NDA)October 2, 2023
Metronidazole68682-202CreamNew drug applications (NDA)August 1, 2023
Azathioprine68682-241TabletGeneric drugs (ANDA)February 4, 2023
Azathioprine68682-231TabletGeneric drugs (ANDA)February 4, 2023
Budesonide68682-658Aerosol, foamNew drug applications (NDA)July 15, 2022
Brinzolamide68682-464Suspension/ dropsGeneric drugs (ANDA)August 25, 2021
Metyrosine68682-310CapsuleAuthorized generics (NDA)September 7, 2020
Clindamycin Phosphate 1.2% and Tretinoin 0.025%68682-300GelAuthorized generics (NDA)August 4, 2020
Isosorbide Dinitrate68682-193TabletNew drug applications (NDA)March 2, 2020
Isosorbide Dinitrate68682-192TabletNew drug applications (NDA)March 2, 2020
Diltiazem Hydrochloride68682-704Tablet, extended releaseAuthorized generics (NDA)October 1, 2019
Tetracaine Hydrochloride68682-920Solution/ dropsNew drug applications (NDA)June 27, 2019
Pimecrolimus68682-112CreamAuthorized generics (NDA)November 26, 2018
Pimecrolimus68682-111CreamAuthorized generics (NDA)November 26, 2018
Pimecrolimus68682-110CreamAuthorized generics (NDA)November 26, 2018
Budesonide68682-309Tablet, extended releaseAuthorized generics (NDA)July 10, 2018
Clindamycin Phosphate and Benzoyl Peroxide68682-132GelAuthorized generics (NDA)July 2, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.